Nektar Therapeutics gains amid takeover speculation

Nektar Therapeutics (NASDAQ:NKTR) rose 8% amid some vague takeover speculation.

There’s speculation that Eli Lilly (NYSE:LLY) could seek an acquisition of Nektar (NASDAQ:NKTR), according to posts on social media. There’s also a report on StreetInsider that talks about the speculation.

Nektar (NKTR) has a market cap of $1.05 billion, and its shares have skyrocketed 294% this year through Thursday. Eli Lilly (NYSE:LLY) is valued at $736 billion.

Eli Lilly (LLY) is set to report Q3 results on Oct. 30.

Leave a Reply

Your email address will not be published. Required fields are marked *